L. Pierre, . Physiologie, . Orthopédie, L. Maintien-À-domicile-isabelle, L. Pharmacologie-cardiovasculaire-dominique et al., Chimie physique générale, Chimie thérapeutique Bertrand RIHN ................................... Biochimie

B. Sandrine, B. Mariette, B. Biologie-cellulaire-emmanuelle, . Communication, B. Santé-isabelle et al., Chimie thérapeutique Chimie thérapeutique

B. Ariane, B. Cédric, C. Jean-claude, C. Chimie-générale-et-minérale-igor, C. Chimie-analytique-joël et al., Chimie thérapeutique, Microbiologie clinique Béatrice FAIVRE ??????????????..Hématologie -Génie Biologique

J. Olivier, . Toxicologie, K. Sécurité-sanitaire-francine, L. Pharmacie-galénique-alexandrine, B. Informatique et al., Hématologie biologique

M. Christophe, M. Microbiologie-environnementale-et-moléculaire-blandine, M. Maxime, P. Pharmacochimie-supramoléculaire-francine, P. Christine et al., Biophysique

S. Anne, S. Pharmacie-galénique-marie-paule, B. Mycologie, T. Nathalie, T. Santé-publique-gabriel et al., Pharmacie galénique PROFESSEUR ASSOCIE, Biochimie et Biologie

C. Christophe, Anglais Bibliothèque Universitaire Santé -Lionnois (Pharmacie -Odontologie) 5

. Le-taux-moyen, Pour 1 des patients le taux d'hémoglobine était supérieur à 11 g/dl. Pour les 3 autres patients, le taux d'hémoglobine est compris entre 9,5 et 10, Au nadir le taux moyen d'hémoglobine du groupe témoin était de 10

. Avant-la-sixième-cure, Les 4 patients avaient un taux de plaquettes supérieur à 100 G/l. Au nadir de cette cure, le taux moyen de plaquettes était de 125

. La-créatininémie-moyenne-Était-de, Au nadir elle n'a été évaluée que pour 1 des patients, Sa créatininémie était de 6

J. Buell, T. Gross, and E. Woodle, Malignancy after Transplantation, Transplantation, vol.80, issue.Supplement, pp.254-64, 2005.
DOI : 10.1097/01.tp.0000186382.81130.ba

M. Moal, Tumeurs solides apr??s transplantation r??nale, N??phrologie & Th??rapeutique, vol.4, pp.214-217, 2008.
DOI : 10.1016/S1769-7255(08)74238-X

W. Sanchez, J. Talwalkar, and G. Gores, ???Will all liver transplantation patients eventually die from cancer????, Journal of Hepatology, vol.44, issue.1, pp.13-18, 2006.
DOI : 10.1016/j.jhep.2005.10.007

L. Kellerman, A. Neugut, B. Burke, and D. Mancini, Comparison of the Incidence of De Novo Solid Malignancies After Heart Transplantation to That in the General Population, The American Journal of Cardiology, vol.103, issue.4, pp.562-568, 2009.
DOI : 10.1016/j.amjcard.2008.10.026

K. Potaris, B. Radovancevic, C. Thomas, I. Gregoric, A. Vaporiciyan et al., Lung Cancer After Heart Transplantation: A 17-Year Experience, The Annals of Thoracic Surgery, vol.79, issue.3, pp.980-83, 2005.
DOI : 10.1016/j.athoracsur.2004.05.021

K. Abu-elmagd, M. Zak, J. Stamos, G. Bond, A. Jain et al., DE NOVO MALIGNANCIES AFTER INTESTINAL AND MULTIVISCERAL TRANSPLANTATION, Transplantation, vol.77, issue.11, pp.1719-1744, 2004.
DOI : 10.1097/01.TP.0000131164.43015.4B

URL : http://pdfs.journals.lww.com/transplantjournal/2004/06150/DE_NOVO_MALIGNANCIES_AFTER_INTESTINAL_AND.16.pdf?token=method|ExpireAbsolute;source|Journals;ttl|1505121305216;payload|mY8D3u1TCCsNvP5E421JYK6N6XICDamxByyYpaNzk7FKjTaa1Yz22MivkHZqjGP4kdS2v0J76WGAnHACH69s21Csk0OpQi3YbjEMdSoz2UhVybFqQxA7lKwSUlA502zQZr96TQRwhVlocEp/sJ586aVbcBFlltKNKo+tbuMfL73hiPqJliudqs17cHeLcLbV/CqjlP3IO0jGHlHQtJWcICDdAyGJMnpi6RlbEJaRheGeh5z5uvqz3FLHgPKVXJzdGlb2qsojlvlytk14LkMXSMx6m5WuzE4AjoVkUM/iVHiDpEI1gRY87mf+RA54S84y;hash|X+bEb9LovI3Duj90s+1WtQ==

M. Guba, C. Graeb, K. Jauch, and E. Geissler, PRO- AND ANTI-CANCER EFFECTS OF IMMUNOSUPPRESSIVE AGENTS USED IN ORGAN TRANSPLANTATION, Transplantation, vol.77, issue.12, pp.1777-82, 2004.
DOI : 10.1097/01.TP.0000120181.89206.54

J. Dantal and E. Pohanka, Malignancies in renal transplantation: an unmet medical need, Nephrology Dialysis Transplantation, vol.22, issue.Supplement 1
DOI : 10.1093/ndt/gfm085

T. Ajithkumar, C. Parkinson, A. Butler, and H. Hatcher, Management of solid tumours in organ-transplant recipients, The Lancet Oncology, vol.8, issue.10, pp.921-953, 2007.
DOI : 10.1016/S1470-2045(07)70315-7

G. Wong and J. Chapman, Cancers after renal transplantation, Transplantation Reviews, vol.22, issue.2, pp.141-150, 2008.
DOI : 10.1016/j.trre.2007.12.004

J. Campistol, J. Albandl, W. Arns, I. Boletis, J. Dantal et al., Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance, Nephrology Dialysis Transplantation, vol.22, issue.Supplement 1, pp.36-41, 2007.
DOI : 10.1093/ndt/gfm090

H. Kauffmann, W. Cherikh, Y. Chang, D. Hanto, and B. Kahan, Maintenance Immunosuppression with Target-of-Rapamycin Inhibitors is Associated with a Reduced Incidence of De Novo Malignancies, Transplantation, vol.80, issue.7, pp.883-892, 2005.
DOI : 10.1097/01.TP.0000184006.43152.8D

A. Jemal, M. Thun, L. Ries, H. Howe, H. Weir et al., Annual Report to the Nation on the Status of Cancer, 1975???2005, Featuring Trends in Lung Cancer, Tobacco Use, and Tobacco Control, JNCI: Journal of the National Cancer Institute, vol.299, issue.11, pp.1672-1694, 1975.
DOI : 10.1001/jama.299.11.1351

G. Institut-de-cancérologie and . Roussy, Mortalité par type de cancer Données disponibles à : http://www.igr.fr/index.php?p_id=84, Consulté le 05 Juillet, 2010.

D. Youlden, S. Cramb, and P. Baade, The International Epidemiology of Lung Cancer: Geographical Distribution and Secular Trends, Journal of Thoracic Oncology, vol.3, issue.8, pp.819-831, 2008.
DOI : 10.1097/JTO.0b013e31818020eb

A. Alberg, J. Ford, and M. Samet, Epidemiology of lung cancer : ACCP evidence-based clinical practice guidelines, Chest, vol.2132, pp.29-55, 2007.

J. Morère, L. Chevalier, and T. , Les cancers intrathoraciques. Collection oncologie pratique

R. Doll and R. Peto, The Causes of Cancer: Quantitative Estimates of Avoidable Risks of Cancer in the United States Today, JNCI: Journal of the National Cancer Institute, vol.66, issue.6, pp.1191-1308, 1981.
DOI : 10.1093/jnci/66.6.1192

D. Trichopoulos, A. Kalandidi, L. Sparros, and B. Mac-mahon, Lung cancer and passive smoking, International Journal of Cancer, vol.302, issue.1, pp.1-4, 1981.
DOI : 10.1002/ijc.2910270102

P. Vincis, G. Hoek, M. Krzyzanowski, F. Vigna-taglianti, F. Veglia et al., Lung cancers attributable to environmental tobacco smoke and air pollution in non-smokers in different European countries: a prospective study, Environmental Health, vol.58, issue.12, p.7, 2007.
DOI : 10.1136/thorax.58.12.1071

K. Jockel, H. Pohlabeln, W. Ahrens, and M. Krauss, Environmental Tobacco Smoke and Lung Cancer, Epidemiology, vol.9, issue.6, pp.672-675, 1998.
DOI : 10.1097/00001648-199811000-00020

A. Schwartz, P. Yang, and G. Swanson, Familial Risk of Lung Cancer among Nonsmokers and Their Relatives, American Journal of Epidemiology, vol.144, issue.6, pp.554-562, 1996.
DOI : 10.1093/oxfordjournals.aje.a008965

O. Catelinois, A. Rogel, D. Laurier, S. Billon, D. Hemon et al., Lung Cancer Attributable to Indoor Radon Exposure in France: Impact of the Risk Models and Uncertainty Analysis, Environmental Health Perspectives, vol.114, issue.9, pp.1361-1366, 2006.
DOI : 10.1289/ehp.9070

URL : https://hal.archives-ouvertes.fr/inserm-00138827

P. Vineis, F. Forastiere, G. Hoek, and M. Lipsett, Outdoor air pollution and lung cancer: Recent epidemiologic evidence, International Journal of Cancer, vol.54, issue.5, pp.647-653, 2004.
DOI : 10.1016/S0027-5107(97)00097-3

URL : http://onlinelibrary.wiley.com/doi/10.1002/ijc.20292/pdf

A. Alberg, R. Yung, P. Strickland, and J. Nelson, Respiratory cancer and exposure to arsenic, chromium, nickel, and polycyclic aromatic hydrocarbons, Clinics in Occupational and Environmental Medicine, vol.2, issue.4, pp.779-801, 2002.
DOI : 10.1016/S1526-0046(02)00056-0

A. Schwartz, Genetic Predisposition to Lung Cancer, Chest, vol.125, issue.5, pp.86-89, 2004.
DOI : 10.1378/chest.125.5_suppl.86S

A. Matakidou, T. Eisen, and R. Houlson, Systematic review of the relationship between family history and lung cancer risk, British Journal of Cancer, vol.27, issue.Suppl 1, pp.825-833, 2005.
DOI : 10.1093/jjco/27.6.415

J. Bailey-wilson, C. Amos, S. Pinney, G. Petersen, D. Andrade et al., A Major Lung Cancer Susceptibility Locus Maps to Chromosome 6q23???25, The American Journal of Human Genetics, vol.75, issue.3, pp.460-74, 2004.
DOI : 10.1086/423857

A. Santillan, C. Camargo, . Jr, and G. Colditz, A meta-analysis of asthma and risk of lung cancer (United States), Cancer Causes and Control, vol.14, issue.4, pp.327-334, 2003.
DOI : 10.1023/A:1023982402137

I. Rouquette, La classification anatomopatologique des cancers bronchopulmonaires, Rev Mal Respir Actual, vol.1, pp.280-291, 2009.
DOI : 10.1016/s1877-1203(09)72496-6

W. Travis, E. Brambilla, H. Muller-hemerlink, and C. Harris, World Health Organisation classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and hear, 2004.

C. Clément-duchêne, Cancer bronchique et facteurs de risque : existe-t-il des marqueurs phénotypiques spécifiques ? Thèse Université Henri Poincaré, 2009.

J. Scullier, La nouvelle classification TNM du cancer bronchqiue, Rev Mal Respir, vol.25, pp.3-40, 2008.

R. Rami-porta, D. Ball, J. Crowley, D. Giroux, J. Jett et al., The IASLC Lung Cancer Staging Project: Proposals for the Revision of the T Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer, Journal of Thoracic Oncology, vol.2, issue.7, pp.593-602, 2007.
DOI : 10.1097/JTO.0b013e31807a2f81

F. Sheperd, J. Crowley, H. Van, P. Postmus, D. Carney et al., The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the Tumor, Node, Metastasis Classification for Lung Cancer, Journal of Thoracic Oncology, vol.2, issue.12, pp.1067-77, 2007.
DOI : 10.1097/JTO.0b013e31815bdc0d

. Oncolor and . Réferentiels, Cancer bronchique non à petites cellules (version du 20 Août, 2009.

M. Alberts and W. , Diagnosis and management of lung cancer executive summary. ACCP Evidence-based clinical practice guideline, Chest, vol.2, issue.132, pp.1-19, 2007.

F. Bertin, A. Guerlin, and M. Laskar, Formes cliniques des cancers thoraciques. Traitement des tumeurs de Pancoast-Tobias, Rev Mal Respir, vol.23, pp.16-164, 2006.

V. Rusch, D. Giroux, M. Kraut, J. Crowley, M. Hazuka et al., Induction Chemoradiation and Surgical Resection for Superior Sulcus Non???Small-Cell Lung Carcinomas: Long-Term Results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160), Journal of Clinical Oncology, vol.25, issue.3, pp.313-318, 2007.
DOI : 10.1200/JCO.2006.08.2826

A. Harle, N. Bayman, R. Califano, P. Lorigan, and C. Faivre-finn, Prise en charge du cancer bronchique ?? petites cellules (CPC) (localis?? et ??tendu), Revue des Maladies Respiratoires Actualit??s, vol.1, issue.4, 2009.
DOI : 10.1016/S1877-1203(09)72517-0

D. Fried, D. Morris, C. Poole, J. Roseneman, J. Halle et al., Systematic Review Evaluating the Timing of Thoracic Radiation Therapy in Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.22, issue.23, pp.4837-4882, 2004.
DOI : 10.1200/JCO.2004.01.178

F. Cappuzzo, T. Ciuleanu, L. Stelmakh, S. Cicena, A. Szczésna et al., Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study, The Lancet Oncology, vol.11, issue.6, pp.521-530, 2010.
DOI : 10.1016/S1470-2045(10)70112-1

M. Wislez, A. Lavolé, and J. Cadranel, Quel traitement en deuxi??me ligne m??tastatique des cancers bronchiques non ?? petites cellules ?, Revue des Maladies Respiratoires Actualit??s, vol.1, issue.4, pp.415-420, 2009.
DOI : 10.1016/S1877-1203(09)72514-5

M. Saynalx, N. Veeramachaneni, J. Hubbs, N. J. Qaquish, B. Bailey et al., Local failure after complete resection of N0-1 non-small cell lung cancer, Lung Cancer, 2010.

J. Dancey, F. Shepherd, R. Grallad, and Y. Kim, Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial, Lung Cancer, vol.43, issue.2, pp.183-94, 2004.
DOI : 10.1016/j.lungcan.2003.09.001

F. Fossella, D. Vore, R. Kerr, R. Crawford, J. Natale et al., Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced nonsmall-cell lung cancer previously treated with platinum-containing chemotherapy regimens

D. Maio, M. Perrone, F. Chiodini, P. Gallo, C. Camps et al., Individual Patient Data Meta-Analysis of Docetaxel Administered Once Every 3 Weeks Compared With Once Every Week Second-Line Treatment of Advanced Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.25, issue.11, pp.1377-82, 2007.
DOI : 10.1200/JCO.2006.09.8251

F. Shepherd, R. Pereira, J. Ciuleanu, T. Tan, E. Hirsh et al., Erlotinib in Previously Treated Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.353, issue.2, pp.123-155, 2005.
DOI : 10.1056/NEJMoa050753

M. Vincent, B. Evans, and I. Smith, First-line chemotherapy rechallenge after relapse in small cell lung cancer, Cancer Chemotherapy and Pharmacology, vol.21, issue.1, pp.45-53, 1988.
DOI : 10.1007/BF00262737

J. Eckardt, V. Pawel, J. Pujol, J. Papai, Z. Quoix et al., Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.25, issue.15, pp.2086-92, 2007.
DOI : 10.1200/JCO.2006.08.3998

D. King and M. Perry, Hepatotoxicity of Chemotherapy, The Oncologist, vol.6, issue.2, pp.162-176, 2001.
DOI : 10.1634/theoncologist.6-2-162

B. Mennecier, A. Gairard-dory, and E. Quoix, Toxicit?? des chimioth??rapies en canc??rologie pulmonaire, EMC - Pneumologie, vol.3, issue.3, pp.6-8, 2006.
DOI : 10.1016/S1155-195X(06)44070-6

M. Aapro, D. Cameron, R. Pettenquell, J. Bohlius, J. Crawford et al., EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours, European Journal of Cancer, vol.42, issue.15, pp.2433-53, 2006.
DOI : 10.1016/j.ejca.2006.05.002

M. Aapro and H. Link, update on EORTC guidelines and anemia management with erythropoiesis-stimulating agent. The Oncologist, pp.33-36, 2007.

L. Moulec, S. Vedrine, and L. , Prise en charge des nausées et vomissements en oncologie thoracique. Revue de Pneumologie clinique, pp.76-80, 2008.

P. Vennin and M. Chazard, Connaître, comprendre et prévenir les effets secondaires des sels de platine. La lettre du cancérologue, pp.225-234, 1993.

G. Saint-lorant, M. J. Galais, M. Lobbedez, T. Chédru-legros, and V. , Hydratation des patients sous cisplatine : enqu??te de pratiques et ??laboration d???un protocole, Th??rapie, vol.60, issue.5, pp.499-505, 2006.
DOI : 10.2515/therapie:2005071

M. Saif, M. Gee, and P. , Hemolytic remic syndrome associated with gemcitabine : a case report and a review of literature, J Pancreas, vol.6, pp.369-74, 2005.

E. Quoix, J. Breton, C. Daniel, P. Jacoulet, D. Debieuvre et al., Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer: A phase II study, Annals of Oncology, vol.12, issue.7, pp.957-62, 2001.
DOI : 10.1023/A:1011171722175

A. Argyriou, E. Chroni, A. Koutras, G. Iconomou, S. Papapetropoulos et al., Preventing Paclitaxel-Induced Peripheral Neuropathy: A Phase II Trial of Vitamin E Supplementation, Journal of Pain and Symptom Management, vol.32, issue.3, pp.237-244, 2006.
DOI : 10.1016/j.jpainsymman.2006.03.013

F. Yerly, A. Mach, S. Kalangos, L. Rotman, V. Segesser et al., Suivi du patient après transplantation cardiaque, monitoring et adaptation de l'immunosuppression, 2009.

J. Chinen and R. Buckle, Transplantation immunology: Solid organ and bone marrow, Journal of Allergy and Clinical Immunology, vol.125, issue.2, pp.324-335, 2010.
DOI : 10.1016/j.jaci.2009.11.014

URL : http://europepmc.org/articles/pmc2857984?pdf=render

J. Pascual, J. Zamora, C. Galeano, A. Royuela, and C. Quereda, Steroïd avoidance or withdrawal for kidney transplant recipient, Ann Intern Med, vol.15, pp.3-11, 2009.

D. Golshayan, M. Pascual, and B. Vogt, Mycophenolic acid formulations in adult renal transplantation. Update on efficacy and tolerability, Ther Clin Risk Manag, vol.5, pp.341-351, 2009.

B. Nankivell, R. Borrows, C. Fung, O. Connell, P. Allen et al., The Natural History of Chronic Allograft Nephropathy, New England Journal of Medicine, vol.349, issue.24, pp.2326-2359, 2003.
DOI : 10.1056/NEJMoa020009

L. Frimat, E. Cassuto-viguier, B. Charpentier, C. Noel, F. Provot et al., Impact of Cyclosporine Reduction With MMF: A Randomized Trial in Chronic Allograft Dysfunction. The 'Reference' Study, American Journal of Transplantation, vol.15, issue.11, pp.2725-2759, 2006.
DOI : 10.1046/j.1600-6143.2005.00779.x

URL : https://hal.archives-ouvertes.fr/inserm-00473412

N. Kamar, L. Frimat, G. Blancho, P. Wolf, M. Delahousse et al., Evaluation of the efficacy and safety of a slow conversion from a calcineurine inhibitor-to sirolimus based therapies in maintenance renal-transplant patient presenting with moderate renal insufficiency, Transplant Int, vol.20, pp.2517-2540, 2007.

S. Study, Reduced exposure to calcineurine inhibitors in renal transplantation, The New England Journal of Medecine, vol.357, pp.2562-75, 2007.

J. Emmanuelle, C. Tosco, S. Merani, and A. Shapiro, Costimulatory blockade with belatacept in clinical and experimental transplantation ??? a review, Expert Opinion on Biological Therapy, vol.8, issue.6, pp.789-96, 2009.
DOI : 10.1097/01.tp.0000332144.71847.97

P. Saas, C. Courivaud, J. Bamoulid, F. Garnache-ottou, E. Seilles et al., Surveillance biologique des patients transplant??s r??naux??: vers une pr??vision des complications associ??es ?? l???immunosuppression???, Annales Pharmaceutiques Fran??aises, vol.66, issue.2, pp.115-121, 2008.
DOI : 10.1016/j.pharma.2008.03.004

M. Biour, Base de données Hépatox Données disponibles à http, 2010.

J. Moro, L. Almenar, L. Martinez-dolz, M. Izquiedero, J. Rueda et al., mTOR inhibitors and their secondary effect in cardiac transplant recipients : a descriptive study

. Agence-de-la-biomédecine, Principaux chiffres nationaux Données accessibles à, Mise à jour du 25, 2009.

D. Taylor, J. Stehlik, L. Edwards, A. P. Christie, J. Dobbels et al., Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Heart Transplant Report???2009, The Journal of Heart and Lung Transplantation, vol.28, issue.10, pp.1007-1029, 2009.
DOI : 10.1016/j.healun.2009.08.014

M. Dandel, H. Lehmkuhl, C. Knosalla, and R. Hetzer, Impact of different long-term maintenance immunosuppressive therapy strategies on patients' outcome after heart transplantation, Transplant Immunology, vol.23, issue.3, pp.93-103, 2010.
DOI : 10.1016/j.trim.2010.04.007

J. Wei, C. Chang, Y. Chuang, and H. Chen, Updates in Heart Transplantation, Transplantation Proceedings, vol.40, issue.8
DOI : 10.1016/j.transproceed.2008.07.112

M. Matignon, K. Dahan, G. Fruchaud, V. Audard, P. Grimbert et al., Transplantation r??nale: indications, r??sultats, limites et??perspectives, La Presse M??dicale, vol.36, issue.12, pp.1829-1863, 2007.
DOI : 10.1016/j.lpm.2007.04.037

. Agence-de-la-biomédecine, Bilan des activitésde greffes et de prélèvements Données disponibles à : http://www.agence-biomedecine.fr/annexes, 2008.

H. Autorité and D. Santé, Synthèse des recommandations professionnelles. Suivi ambulatoire de l'adulte transplanté rénal au-delà de 3 mois après transplantation, 2007.

D. Anglicheau, N. Pallet, M. Rabant, P. Marquet, B. Cassinat et al., Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine???sirolimus interaction, Kidney International, vol.70, issue.6, pp.1019-1025, 2006.
DOI : 10.1038/sj.ki.5001649

C. Jerdi, P. Desmeules, and P. Dayer, La glycoprotéine P : un transporteur de médicaments à ne pas négliger, Revue Médicale Suisse, vol.524, 2004.

O. Dahl, G. Vagstad, and B. Iversen, Cisplatin-Based Chemotherapy in a Renal Transplant Recipient with Metastatic Germ Cell Testicular Cancer, Acta Oncologica, vol.73, issue.6, pp.759-61, 1996.
DOI : 10.1002/1097-0142(19940101)73:1<196::AID-CNCR2820730134>3.0.CO;2-F

P. Killenberg, Drug Interactions with Commonly used Immunosuppressive Agents
DOI : 10.1002/9780470751541.ch30

P. Killenberg and P. Clavien, Medical care of the liver transplant patient : total pre-, intraand post-operative management, Massachussetts. Blackwell Science Inc, pp.522-557, 2006.
DOI : 10.1002/9780470751541

T. Kawaguchi, M. Takada, A. Kubo, A. Matsmura, S. Fukai et al., Gender, Histology, and Time of Diagnosis Are Important Factors for Prognosis: Analysis of 1499 Never-Smokers with Advanced Non-small Cell Lung Cancer in Japan, Journal of Thoracic Oncology, vol.5, issue.7, pp.1011-1018, 2010.
DOI : 10.1097/JTO.0b013e3181dc213e

Z. Ahmed, M. Marshall, J. Kucharczuk, L. Kaiser, and J. Shrager, Lung Cancer in Transplant Recipients, Archives of Surgery, vol.139, issue.8, pp.902-906, 2004.
DOI : 10.1001/archsurg.139.8.902

H. Tan, M. Fiel, D. R. Martin, J. Schiano, and T. , Graft rejection occurring in post-liver transplant patients receiving cytotoxic chemotherapy: A case series, Liver Transplantation, vol.12, issue.6, pp.634-639, 2009.
DOI : 10.4049/jimmunol.164.12.6230